Cover Image
市場調查報告書

綠色膿菌感染疾病:開發平台分析

Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 271819
出版日期 內容資訊 英文 250 Pages
訂單完成後即時交付
價格
Back to Top
綠色膿菌感染疾病:開發平台分析 Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016
出版日期: 2016年12月07日 內容資訊: 英文 250 Pages
簡介

綠膿菌是宿主抵抗力特別低落的患者感染的原因。是住院一週以上患者身上所分離出最常見的病原菌。常見的症狀有肺炎,發燒,疲勞,發癢的皮疹,出血性潰瘍,頭痛等。危險因子有老年及免疫系統低落等。

本報告提供綠色膿菌感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表,及正在開發的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍
  • 綠色膿菌感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aeolus Pharmaceuticals, Inc.
  • AlgiPharma AS
  • Allergan Plc
  • AmpliPhi Biosciences Corporation
  • AnGes MG, Inc.
  • Arch Biopartners, Inc.
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Biolytics Pharma
  • ConjuGon, Inc.
  • CSA Biotechnologies LLC
  • F. Hoffmann-La Roche Ltd.
  • FOB Synthesis, Inc.
  • GlaxoSmithKline Plc
  • GlycoMimetics, Inc.
  • Helix BioMedix, Inc.
  • Insmed Incorporated
  • LegoChem Biosciences, Inc
  • Lytix Biopharma AS
  • MedImmune, LLC
  • Melinta Therapeutics, Inc
  • Microbiotix, Inc.
  • Northern Antibiotics Oy
  • Nosopharm SAS
  • Novabiotics Limited
  • Novan, Inc.
  • Omnia Molecular Ltd.
  • Pfizer Inc.
  • Pherecydes Pharma SA
  • Phico Therapeutics Limited
  • Phylogica Limited
  • Polyphor Ltd.
  • Procarta Biosystems Ltd
  • Sarepta Therapeutics, Inc.
  • Sealife PHARMA GMBH
  • Sequoia Sciences, Inc.
  • 鹽野義製藥
  • Soligenix, Inc.
  • Spider Biotech
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.
  • Trana Discovery, Inc.
  • Valneva SE
  • Vaxdyn, S.L.
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (fosfomycin + tobramycin)
  • AA-139
  • ACHN-975 Prodrug
  • Aerucin
  • AG-30/5C
  • amikacin liposomal
  • AmpliPHAGE-001
  • Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections
  • Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections
  • APT-1026
  • AR-104
  • Biologic for Pseudomonas Aeruginosa Infection
  • BXN-112
  • Cell Therapy for GBM and Pseudomonas Aeruginosa Infections
  • Cephalosporin + Beta-Lactamase Inhibitor
  • CSA-13
  • dehydroleucodine
  • Drug for Infectious Diseases
  • Drug for Psuedomonas aeruginosa Respiratory Infections
  • dusquetide
  • FSI-1671
  • FSI-1686
  • G-10
  • GMI-1051
  • GN snare
  • GN-4474
  • HB-1345
  • HT-05
  • KBP-7963
  • LCB-100200
  • LTX-109
  • MBX-2359
  • MDN-0057
  • Monoclonal Antibodies for Gram-Negative Bacterial Infections
  • NAB-7061
  • NAB-739
  • NAB-741
  • NBTI-5463
  • NOSO-95300
  • NP-432
  • NVN-1000
  • NVN-4428
  • Oligomer G for Pseudomonas Aeruginosa Infectious
  • Panaecin
  • POL-7080 Follow-On
  • PP-1131
  • Pseudomonas aeruginosa vaccine
  • Pseudomonas aeruginosa vaccine
  • Pseudomonas aeruginosa vaccine
  • Pseudomonas aeruginosa vaccine
  • pseudomonas and VAP conjugate vaccine
  • PT-3.1
  • PT-3.33
  • RX-05
  • RXP-763
  • RXP-766
  • RXP-770
  • RXP-792
  • RXP-793
  • RXP-808
  • RXP-873
  • S-649266
  • SB-041
  • Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections
  • SLP-0901
  • Small Molecule 2 to Inhibit Lectin B for Pseudomonas Aeruginosa Infections
  • Small Molecule for Bacterial Infections
  • Small Molecule for Gram-Negative Nosocomial Infections
  • Small Molecule to Inhibit Lectin B for Pseudomonas Aeruginosa Infections
  • Small Molecule to Inhibit Lectins for Pseudomonas Infections
  • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
  • Small Molecules for Bacterial Infections
  • Small Molecules for Gram-Negative Bacterial Infections
  • Small Molecules for Gram-Negative Bacterial Infections
  • Small Molecules for Gram-Negative Bacterial Infections and Pseudomonas Aeruginosa Infections
  • Small Molecules for Multi-Drug Resistant Bacterial Infections
  • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections
  • Small Molecules for Pseudomonas Aeruginosa Infection and Inflammation
  • Small Molecules for Resistant Pseudomonas aeruginosa Infections
  • Small Molecules to Inhibit LasB for Pseudomonas Aeruginosa Infections
  • Small Molecules to Inhibit LasR Receptor for Lung Infections and Pseudomonas aeruginosa Infections
  • Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections
  • Small Molecules to Inhibit PqsD for Pseudomonas Aeruginosa Infections
  • Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections
  • Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections
  • Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections
  • Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease
  • TP-433
  • TP-559
  • V-2L2MD
  • VLA-43
  • VXD-002
  • ZP-044
  • ZP-046

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8783IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 3, 52, 22 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 11, 12 and 1 molecules, respectively.Pseudomonas aeruginosa Infections.

Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 5
  • Pseudomonas aeruginosa Infections Overview 6
  • Therapeutics Development 7
  • Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies 9
  • Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 13
  • Pseudomonas aeruginosa Infections - Pipeline Products Glance 15
  • Pseudomonas aeruginosa Infections - Products under Development by Companies 19
  • Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes 24
  • Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 26
  • Pseudomonas aeruginosa Infections - Therapeutics Assessment 76
  • Drug Profiles 88
  • Pseudomonas aeruginosa Infections - Dormant Projects 220
  • Pseudomonas aeruginosa Infections - Discontinued Products 225
  • Pseudomonas aeruginosa Infections - Product Development Milestones 226
  • Appendix 237

List of Tables

  • Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2016 19
  • Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016 20
  • Number of Products under Development by Companies, H2 2016 21
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 22
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 23
  • Number of Products under Development by Companies, H2 2016 (Contd..3) 24
  • Number of Products under Investigation by Universities/Institutes, H2 2016 26
  • Comparative Analysis by Late Stage Development, H2 2016 27
  • Comparative Analysis by Clinical Stage Development, H2 2016 28
  • Comparative Analysis by Early Stage Development, H2 2016 29
  • Comparative Analysis by Unknown Stage Development, H2 2016 30
  • Products under Development by Companies, H2 2016 31
  • Products under Development by Companies, H2 2016 (Contd..1) 32
  • Products under Development by Companies, H2 2016 (Contd..2) 33
  • Products under Development by Companies, H2 2016 (Contd..3) 34
  • Products under Development by Companies, H2 2016 (Contd..4) 35
  • Products under Investigation by Universities/Institutes, H2 2016 36
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 37
  • Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc, H2 2016 38
  • Pseudomonas aeruginosa Infections - Pipeline by Adenium Biotech ApS, H2 2016 39
  • Pseudomonas aeruginosa Infections - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 40
  • Pseudomonas aeruginosa Infections - Pipeline by AlgiPharma AS, H2 2016 41
  • Pseudomonas aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corp, H2 2016 42
  • Pseudomonas aeruginosa Infections - Pipeline by AnGes MG Inc, H2 2016 43
  • Pseudomonas aeruginosa Infections - Pipeline by Arch Biopartners, Inc., H2 2016 44
  • Pseudomonas aeruginosa Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 45
  • Pseudomonas aeruginosa Infections - Pipeline by Arno Therapeutics Inc, H2 2016 46
  • Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2016 47
  • Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2016 48
  • Pseudomonas aeruginosa Infections - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 49
  • Pseudomonas aeruginosa Infections - Pipeline by Cellceutix Corp, H2 2016 50
  • Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC, H2 2016 51
  • Pseudomonas aeruginosa Infections - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 52
  • Pseudomonas aeruginosa Infections - Pipeline by Evaxion Biotech ApS, H2 2016 53
  • Pseudomonas aeruginosa Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 54
  • Pseudomonas aeruginosa Infections - Pipeline by FOB Synthesis Inc, H2 2016 55
  • Pseudomonas aeruginosa Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 56
  • Pseudomonas aeruginosa Infections - Pipeline by Helix BioMedix Inc, H2 2016 57
  • Pseudomonas aeruginosa Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016 58
  • Pseudomonas aeruginosa Infections - Pipeline by Immun System IMS AB, H2 2016 59
  • Pseudomonas aeruginosa Infections - Pipeline by Insmed Inc, H2 2016 60
  • Pseudomonas aeruginosa Infections - Pipeline by Lascco SA, H2 2016 61
  • Pseudomonas aeruginosa Infections - Pipeline by Laurent Pharmaceuticals Inc, H2 2016 62
  • Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences Inc, H2 2016 63
  • Pseudomonas aeruginosa Infections - Pipeline by Lytix Biopharma AS, H2 2016 64
  • Pseudomonas aeruginosa Infections - Pipeline by MedImmune LLC, H2 2016 65
  • Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics Inc, H2 2016 66
  • Pseudomonas aeruginosa Infections - Pipeline by Microbiotix Inc, H2 2016 67
  • Pseudomonas aeruginosa Infections - Pipeline by Nosopharm SAS, H2 2016 68
  • Pseudomonas aeruginosa Infections - Pipeline by Novabiotics Ltd, H2 2016 69
  • Pseudomonas aeruginosa Infections - Pipeline by Omnia Molecular Ltd, H2 2016 70
  • Pseudomonas aeruginosa Infections - Pipeline by Peptilogics Inc, H2 2016 71
  • Pseudomonas aeruginosa Infections - Pipeline by Pfizer Inc, H2 2016 72
  • Pseudomonas aeruginosa Infections - Pipeline by Pherecydes Pharma SA, H2 2016 73
  • Pseudomonas aeruginosa Infections - Pipeline by Phico Therapeutics Ltd, H2 2016 74
  • Pseudomonas aeruginosa Infections - Pipeline by Polyphor Ltd, H2 2016 75
  • Pseudomonas aeruginosa Infections - Pipeline by Procarta Biosystems Ltd, H2 2016 76
  • Pseudomonas aeruginosa Infections - Pipeline by Sanofi, H2 2016 77
  • Pseudomonas aeruginosa Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016 78
  • Pseudomonas aeruginosa Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 79
  • Pseudomonas aeruginosa Infections - Pipeline by Sequoia Sciences Inc, H2 2016 80
  • Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd, H2 2016 81
  • Pseudomonas aeruginosa Infections - Pipeline by Soligenix Inc, H2 2016 82
  • Pseudomonas aeruginosa Infections - Pipeline by Syntiron LLC, H2 2016 83
  • Pseudomonas aeruginosa Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 84
  • Pseudomonas aeruginosa Infections - Pipeline by Varinel Inc, H2 2016 85
  • Pseudomonas aeruginosa Infections - Pipeline by Vaxdyn SL, H2 2016 86
  • Pseudomonas aeruginosa Infections - Pipeline by Zambon Company SpA, H2 2016 87
  • Assessment by Monotherapy Products, H2 2016 88
  • Assessment by Combination Products, H2 2016 89
  • Number of Products by Stage and Target, H2 2016 91
  • Number of Products by Stage and Mechanism of Action, H2 2016 94
  • Number of Products by Stage and Route of Administration, H2 2016 97
  • Number of Products by Stage and Molecule Type, H2 2016 99
  • Pseudomonas aeruginosa Infections - Dormant Projects, H2 2016 232
  • Pseudomonas aeruginosa Infections - Dormant Projects (Contd..1), H2 2016 233
  • Pseudomonas aeruginosa Infections - Dormant Projects (Contd..2), H2 2016 234
  • Pseudomonas aeruginosa Infections - Dormant Projects (Contd..3), H2 2016 235
  • Pseudomonas aeruginosa Infections - Dormant Projects (Contd..4), H2 2016 236
  • Pseudomonas aeruginosa Infections - Discontinued Products, H2 2016 237

List of Figures

  • Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2016 19
  • Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016 20
  • Number of Products under Development by Companies, H2 2016 21
  • Number of Products under Investigation by Universities/Institutes, H2 2016 25
  • Comparative Analysis by Late Stage Development, H2 2016 27
  • Comparative Analysis by Clinical Stage Development, H2 2016 28
  • Comparative Analysis by Early Stage Products, H2 2016 29
  • Comparative Analysis by Unknown Stage Development, H2 2016 30
  • Assessment by Monotherapy Products, H2 2016 88
  • Assessment by Combination Products, H2 2016 89
  • Number of Products by Top 10 Targets, H2 2016 90
  • Number of Products by Stage and Top 10 Targets, H2 2016 90
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 93
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 93
  • Number of Products by Routes of Administration, H2 2016 96
  • Number of Products by Stage and Routes of Administration, H2 2016 96
  • Number of Products by Top 10 Molecule Types, H2 2016 98
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 98
Back to Top